Envoy Medical, Inc. COCHW

Q3 FY2026 · ended Sep 30, 2026 · Revenue $66,000, +57.1% YoY · Filed Nov 5, 2026

Envoy Medical, Inc. (COCH) files with the SEC under industry code 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $66,000 and a net loss of $3.9 million. Free cash flow was -$5.1 million.

Revenue
$66,000
+57.1% vs year-ago quarter
Net income
$-3.93M
+39.3% vs year-ago quarter
Operating cash flow
$-5.03M
-16.1% vs year-ago quarter
Free cash flow
$-5.06M
-16.8% vs year-ago quarter
EPS
$-0.50
+85.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
7.74M
-73.1% vs year-ago quarter
Net cash
$2.82M
Q4 FY2025
Operating margin
-10343.3%
TTM

Company profile

Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Listed as
COCH (Nasdaq), COCHW (Nasdaq)
Fiscal year ends
December 31
Headquarters
White Bear Lake, MN
SEC filer status
, Emerging growth company
SEC CIK
1840877
Former names
Anzu Special Acquisition Corp I (until Sep 29, 2023)

Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Line
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Revenue
$66,000
$51,000
$39,000
$75,000
$42,000
Operating income
-$5.5M
-$5.6M
-$6.0M
-$6.8M
-$5.3M
Net income
-$3.9M
-$6.0M
-$4.4M
-$6.6M
-$6.5M
Diluted EPS
-$0.50
-$0.07
-$0.08
-$0.09
-$3.55
Operating cash flow
-$5.0M
-$5.5M
-$6.1M
-$5.7M
-$4.3M
Free cash flow
-$5.1M
-$5.5M
—
-$5.9M
-$4.3M
Total assets
$19.2M
$23.9M
$29.8M
$8.6M
$8.2M
Total liabilities
$20.3M
$20.3M
$19.3M
$20.3M
$15.7M
Stockholders' equity
-$1.5M
$3.3M
$10.2M
-$12.2M
-$7.7M
Cash and investments
$14.6M
$19.7M
$25.3M
$3.7M
$3.6M
Total debt
—
—
—
$919,000
—

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
Oct 27, 2026 Oct 23, 2026
8-K Current report
Shareholder vote results
Oct 16, 2026 Oct 12, 2026
8-K Current report
Other events
Oct 7, 2026 Oct 6, 2026
8-K Current report
Officer or director change
Aug 27, 2026 Aug 24, 2026
8-K Current report
Results of operations
Aug 10, 2026 Aug 10, 2026
10-Q Quarterly report Aug 10, 2026 Jun 30, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.